

18-19 May 2018 Barcelona, Catalonia, Spain

Screening for Neurocognitive

Impairment in HIV Infection

Jose A. Muñoz-Moreno, Ph.D.

Lluita contra la SIDA Foundation Germans Trias i Pujol University Hospital Badalona, Barcelona Catalonia, Spain





Two Key Screenings

Screening for Neurocognitive Impairment

1.

2. Screening for Neuropsychiatric Disorders



Muñoz-Moreno/Barcelona/May 2018

Two Key Screenings

Screening for Neurocognitive Impairment

1.

2. Screening for Neuropsychiatric Disorders

Advantages in common:

- 1. Feasible: paper-based
- 2. Rapid: <10 minutes
- 3. Reliable: 75% 95%



Name	Reference	Duratio n	Pros	Cons
CogState®	Cysique et al, J Int Neuropsych Soc, 2006	10-15 min	 - 4 areas covered - Low practice effect 	 Economical cost Feasibility (computerized)
CAMCI® (Computer Assessment of Mild Cogn. Impairm.)	Becker et al, AIDS Patient Care and STDs, 2011	20 min	 4 areas covered Low practice effect 	- Economical cost - Feasibility (computerized)
HNRC Screen	Carey et al, Clin Neuropsychol, 2004	5-10 min	- Good accuracy (78%, 85%) - Only 2 measures	 Economical cost Instrumental requirements (pegboard)
IHDS (International HIV Dementia Scale)	Sacktor et al, AIDS, 2005	5-10 min	- Quantitative score - Extensively used	- Designed for HAD - Limited accuracy
BNCS (Brief NeuroCognitive Screen)	Ellis et al, J Neurovirol, 2005	5-10 min	- Paper-based use - Extensively used	- Economical cost - Limited sensitivity (65%)
MoCA® (Montreal Cognitive Assessment)	Koski et al, HIV Medicine, 2011	5-10 min	- Quantitative score - 4 areas covered	 Designed for aging Limited specificity (42%)
NEU Screen	Muñoz-Moreno et al, JAIDS, 2013	5-10 min	- Good accuracy (74%, 81%) - No copyright restrictions	- Limited to Spanish speakers - No formal validation

Name	Reference	Duratio n	Pros	Cons
CogState®	Cysique et al, J Int Neuropsych Soc, 2006	10-15 min	 4 areas covered Low practice effect 	- Economical cost - Feasibility (computerized)
CAMCI® (Computer Assessment of Mild Cogn. Impairm.)	Becker et al, AIDS Patient Care and STDs, 2011	20 min	 4 areas covered Low practice effect 	- Economical cost - Feasibility (computerized)
HNRC Screen	Carey et al, Clin Neuropsychol, 2004	5-10 min	- Good accuracy (78%, 85%) - Only 2 measures	 Economical cost Instrumental requirements (pegboard)
IHDS (International HIV Dementia Scale)	Sacktor et al, AIDS, 2005	5-10 min	- Quantitative score - Extensively used	- Designed for HAD - Limited accuracy
BNCS (Brief NeuroCognitive Screen)	Ellis et al, J Neurovirol, 2005	5-10 min	- Paper-based use - Extensively used	- Economical cost - Limited sensitivity (65%)
MoCA® (Montreal Cognitive Assessment)	Koski et al, HIV Medicine, 2011	5-10 min	 Quantitative score 4 areas covered 	- Designed for aging - Limited specificity (42%)
NEU Screen	Muñoz-Moreno et al, JAIDS, 2013	5-10 min	- Good accuracy (74%, 81%) - No copyright restrictions	 Limited to Spanish speakers No formal validation

Name	Reference	Duratio n	Pros	Cons
CogState®	Cysique et al, J Int Neuropsych Soc, 2006	10-15 min	 4 areas covered Low practice effect	- Economical cost - Feasibility (computerized)
CAMCI® (Computer Assessment of Mild Cogn. Impairm.)	Becker et al, AIDS Patient Care and STDs, 2011	20 min	 4 areas covered Low practice effect	- Economical cost - Feasibility (computerized)
HNRC Screen	Carey et al, Clin Neuropsychol, 2004	5-10 min	- Good accuracy (78%, 85%) - Only 2 measures	 Economical cost Instrumental requirements (pegboard)
IHDS (International HIV Dementia Scale)	Sacktor et al, AIDS, 2005	5-10 min	- Quantitative score - Extensively used	- Designed for HAD - Limited accuracy
BNCS (Brief NeuroCognitive Screen)	Ellis et al, J Neurovirol, 2005	5-10 min	- Paper-based use - Extensively used	- Economical cost - Limited sensitivity (65%)
MoCA® (Montreal Cognitive Assessment)	Koski et al, HIV Medicine, 2011	5-10 min	 Quantitative score 4 areas covered 	 Designed for aging Limited specificity (42%)
NEU Screen	Muñoz-Moreno et al, JAIDS, 2013	5-10 min	- Good accuracy (74%, 81%) - No copyright restrictions	- Limited to Spanish speakers - No formal validation

Name	Reference	Duratio n	Pros	Cons
CogState®	Cysique et al, J Int Neuropsych Soc, 2006	10-15 min	 4 areas covered Low practice effect 	 Economical cost Feasibility (computerized)
CAMCI® (Computer Assessment of Mild Cogn. Impairm.)	Becker et al, AIDS Patient Care and STDs, 2011	20 min	- 4 areas covered - Low practice effect	- Economical cost - Feasibility (computerized)
HNRC Screen	Carey et al, Clin Neuropsychol, 2004	5-10 min	- Good accuracy (78%, 85%) - Only 2 measures	 Economical cost Instrumental requirements (pegboard)
IHDS (International HIV Dementia Scale)	Sacktor et al, AIDS, 2005	5-10 min	- Quantitative score - Extensively used	- Designed for HAD - Limited accuracy
BNCS (Brief NeuroCognitive Screen)	Ellis et al, J Neurovirol, 2005	5-10 min	- Paper-based use - Extensively used	- Economical cost - Limited sensitivity (65%)
MoCA® (Montreal Cognitive Assessment)	Koski et al, HIV Medicine, 2011	5-10 min	- Quantitative score - 4 areas covered	- Designed for aging - Limited specificity (42%)
NEU Screen	Muñoz-Moreno et al, JAIDS, 2013	5-10 min	- Good accuracy (74%, 81%) - No copyright restrictions	- Limited to Spanish speakers - No formal validation

Name	Reference	Duratio n	Pros	Cons
CogState®	Cysique et al, J Int Neuropsych Soc, 2006	10-15 min	 4 areas covered Low practice effect 	 Economical cost Feasibility (computerized)
CAMCI® (Computer Assessment of Mild Cogn. Impairm.)	Becker et al, AIDS Patient Care and STDs, 2011	20 min	 4 areas covered Low practice effect 	 Economical cost Feasibility (computerized)
HNRC Screen	Carey et al, Clin Neuropsychol, 2004	5-10 min	- Good accuracy (78%, 85%) - Only 2 measures	 Economical cost Instrumental requirements (pegboard)
IHDS (International HIV Dementia Scale)	Sacktor et al, AIDS, 2005	5-10 min	- Quantitative score - Extensively used	- Designed for HAD - Limited accuracy
BNCS (Brief NeuroCognitive Screen)	Ellis et al, J Neurovirol, 2005	5-10 min	- Paper-based use - Extensively used	- Economical cost - Limited sensitivity (65%)
MoCA [®] (Montreal Cognitive Assessment)	Koski et al, HIV Medicine, 2011	5-10 min	- Quantitative score - 4 areas covered	 Designed for aging Limited specificity (42%)
NEU Screen	Muñoz-Moreno et al, JAIDS, 2013	5-10 min	- Good accuracy (74%, 81%) - No copyright restrictions	 Limited to Spanish speakers No formal validation









e <u>Aging</u>

e <u>Accuracy</u>

MoCA (Nasreddine et al, JAGS, 2005)

NEU Screen (Muñoz-Moreno et al, JAIDS, 2013)

Hasbun et al, J AIDS Clin Res, 2012	Age 43: 85% - 40%
Overton et al, J Neurovirol, 2013	Age 43: 89% - 42%
Milanini et al, JAIDS, 2014	Age >60: 72% - 67%
Muñoz-Moreno et al, JAIDS, 2013	Age 44: 81% - 74%
Muñoz-Moreno et al, CROI, 2014	Age 43: 73% - 74%
Muñoz-Moreno et al, submitted, 2018	Age >60: 91% - 92%



2. Neuropsychiatric Symptoms



Muñoz-Moreno / Barcelona / May 2018

CONCLUSIONS

1. Both neurocognitive and neuropsychiatric screenings are essential in the establishment of a HAND.

2. There are available feasible and rapid tools for both type of screenings.

3. Accuracy of some of those tools can be fairly high, particularly for aging HIV population.

